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Abstract
Background: Epstein-Barr virus (EBV)-driven B cell proliferation is critical to its subsequent persistence in the host
and is a key event in the development of EBV-associated B cell diseases. Thus, inquiry into early cellular events that
precede EBV-driven proliferation of B cells is essential for understanding the processes that can lead to EBV-
associated B cell diseases.
Methods: Infection with high titers of EBV of mixed, primary B cells in different stages of differentiation occurs
during primary EBV infection and in the setting of T cell-immunocompromise that predisposes to development of
EBV-lymphoproliferative diseases. Using an ex vivo system that recapitulates these conditions of infection, we
correlated expression of selected B cell-surface markers and intracellular cytokines with expression of EBV latency
genes and cell proliferation.
Results: We identified CD23, CD58, and IL6, as molecules expressed at early times after EBV-infection. EBV
differentially infected B cells into two distinct sub-populations of latently infected CD23
+ cells: one fraction, marked
as CD23
hiCD58
+IL6
- by day 3, subsequently proliferated; another fraction, marked as CD23
loCD58
+, expressed IL6, a
B cell growth factor, but failed to proliferate. High levels of LMP1, a critical viral oncoprotein, were expressed in
individual CD23
hiCD58
+ and CD23
loCD58
+ cells, demonstrating that reduced levels of LMP1 did not explain the
lack of proliferation of CD23
loCD58
+ cells. Differentiation stage of B cells did not appear to govern this dichotomy
in outcome either. Memory or naïve B cells did not exclusively give rise to either CD23
hi or IL6-expressing cells;
rather memory B cells gave rise to both sub-populations of cells.
Conclusions: B cells are differentially susceptible to EBV-mediated proliferation despite expression of viral gene
products known to be critical for continuous B cell growth. Cellular events, in addition to viral gene expression,
likely play a critical role in determining the outcome of EBV infection. By indentifying cells predicted to undergo
EBV-mediated proliferation, our study provides new avenues of investigation into EBV pathogenesis.
Background
Infection of B cells with Epstein-Barr virus (EBV) leads
to proliferation and subsequent immortalization, result-
ing in establishment of lymphoblastoid cell lines in vitro
(LCL). LCL-like cells are observed during primary EBV
infection [1], in tonsils of healthy individuals [2,3], and
are characteristic of EBV-associated lymphomas and
lymphoproliferative diseases in immunocompromised
hosts [4]. EBV-driven B cell proliferation is essential for
development of such tumors in vivo and for outgrowth
into LCL ex vivo.Al a r g eb o d yo fe v i d e n c eh a s
established that EBV proteins EBNA2 and LMP1 [5-10]
are critical viral oncoproteins that are required for
growth transformation of B cells. Regarding cellular
events that follow EBV infection, with some exceptions
[6,11], most studies have focused on late events such as
outgrowth of LCL, 3 to 8 weeks after infection with
EBV [12,13]. While CD23, the low affinity receptor for
IgE, was found to be expressed early on cells undergoing
immortalization [6,11], little is known about the exact
relationship between CD23 expression at early times,
expression of viral latency genes, and subsequent prolif-
eration or immortalization [14,15]. To better understand
EBV pathogenesis, it is important to dissect early
host cell processes that precede EBV-driven B cell
proliferation.
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tion with EBV in healthy individuals and the early stages of
development of B cell-EBV lymphoproliferative diseases/
lymphomas in immunocompromised hosts are character-
ized by infection of polyclonal B cells in different stages of
differentiation by high titers of EBV in the absence of EBV-
specific protective immune responses. Using an ex vivo sys-
tem that emulates these conditions, we sought the identity
of B cells that underwent proliferation after exposure of
total peripheral B cells to high titers of EBV in the absence
of EBV-specific immune responses. B cell surface markers,
intracellular cytokines, and expression of EBV genes were
interrogated simultaneously and correlated with cell prolif-
eration to identify a specific sub-population of B cells sus-
ceptible to EBV-driven proliferation.
Results
Exposure to EBV results in differential levels of expression
of CD23
B cells undergoing EBV-driven immortalization express
high levels of CD23 [6,7]. We examined the kinetics of
expression of CD23 on CD23
+ cells at early times follow-
i n ge x p o s u r eo ft o t a lp r i m a r yBc e l l st oE B V .F i g u r e1
shows that following exposure to EBV, the fraction of
CD23
+ cells that expressed high levels of CD23 (CD23
hi)
increased. There was a rapid shift in the pattern of CD23
expression from 2.3% CD23
hi cells at time 0 to 59.6%
CD23
hi cells at 90 h resulting in a 25.9-fold increase at
9 0hr e l a t i v et ot i m e0 .T h e r e f o r e ,e x p o s u r et oE B V
resulted in sub-populations of B cells with differential
levels of expression of CD23. No alterations in expression
of CD23 from baseline were observed when un-infected
cells were cultured (data not shown).
CD58, CD23, and IL6, the earliest expressed molecules,
mark the emergence of distinct sub-populations of B cells
after exposure to EBV
To distinguish distinct sub-populations within CD23
+ B
cells early after exposure to EBV, we correlated
expression of CD23 with expression of other B cell mar-
kers including CD58, IL6, CD57, CD86, HLA Class II,
PD1, and IL10. Table 1 shows that there was a rapid
increase in the fraction of CD23
+ cells that expressed
CD58 in the first 18 h relative to time 0 (9.7-fold in sub-
ject 1 and 21.5-fold in subject 2). While nearly a third of
CD23
- cells expressed CD58 at time 0, there was less
than a two-fold increase over the duration of the experi-
ments. Thus among CD23
+ cells, there was a rapid
increase in expression of CD58.
Intracellular expression of IL6 increased in CD23
+
cells by 42 to 66 h (15.8-fold at 42 h in subject 1 and
24.1-fold at 66 h in subject 2) as compared to time 0.
Very few CD23
- cells expressed IL6. CD57 expression
increased substantially on CD23
+ cells (15.8-fold) at
42 h in only subject 1. No substantial change in
expression on CD23
+ cells was observed for the other
molecules. Although levels of expression of CD58
(LFA3), an adhesion molecule, and the cytokine IL6
altered most rapidly following exposure to EBV,
expression of CD58 on CD23
+ cells was the earlier
marker of infection with EBV.
Next, we examined whether there was a correlation
between the level of expression of CD23 and CD58.
Figure 2 shows B cells from a representative healthy
EBV-seropositive subject (A) and a representa-
tive healthy EBV-seronegative subject (B) that were
un-treated or exposed to EBV for four days. When
compared with un-infected cells, two distinct
sub-populations of CD23
+ cells emerged after EBV
infection. Sub-population R2 was characterized by
expression of CD58 and low levels of expression of
CD23 (CD23
loCD58
+) while sub-population R3
expressed CD58 and high levels of CD23 (CD23
hiCD58
+). Thus, two distinct sub-populations of B cells could
be identified based on presence of CD58 and either
high or low level of expression of CD23 early after
exposure to EBV of cells from both EBV-seropositive
and -seronegative individuals.
Figure 1 Exposure to EBV results in differential levels of expression of CD23 on B cells. Expression of CD23 was determined using PE-anti-
CD23 antibody at 0 h, 18 h, 42 h, 66 h, and 90 h after exposure of B cells to EBV. Percent CD23
+ cells expressing low levels or high levels of
CD23 (CD23
hi) are shown.
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Page 2 of 12Expression of CD58 but not IL6 correlates with
proliferation of EBV-exposed cells
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+
cells, we asked if any of these markers correlated with
proliferation of cells. To examine proliferation, we
labeled B cells with CFSE prior to exposure to EBV.
CFSE is redistributed equally among daughter cells
resulting in approximate halving of fluorescence inten-
sity with each round of proliferation. A representative
experiment shows that five days after exposure to EBV,
15.3% (G1+G2+G3) of CD58
+ cells had proliferated
(Figure 3A) and approximately 5% of cells had under-
gone more than one round of proliferation. In compari-
son, none of the CD58
- cells had undergone more than
one round of proliferation. Among CD58
+ cells, 38.5%
expressed IL6 while only 0.3% of CD58
- cells expressed
IL6. Thus, although CD58 expression was associated
with expression of IL6, proliferating cells expressed
CD58 but not IL6. Results of Figure 3A show that there
were at least three sub-groups of CD58
+ cells: one
group that proliferated but did not express IL6, another
that expressed IL6 but did not proliferate, and a third
that did neither.
The expression pattern CD23
hiCD58
+IL6
- marks cells that
proliferate
To determine how expression of CD58 correlated with
proliferation, we temporally followed the evolution of the
two CD23
+CD58
+ sub-populations and the CD23
+CD58
-
sub-population after exposure to EBV. Figure 3B shows
that there was an approximate doubling in the fraction of
cells in R3 (CD23
hiCD58
+ c e l l s )f r o m2 . 3 %t o4 . 8 %
between day 5 and day 6 and from 4.8% to 9.5% between
day 6 and day 7. In contrast, the two other sub-popula-
tions R1 (CD23
loCD58
- cells) and R2 (CD23
loCD58
+
cells) did not show a similar doubling. Tracking the three
sub-populations from day 4 to day 30 revealed a progres-
sive increase in the fraction of CD23
hiCD58
+ cells result-
ing in the exclusive presence of CD23
hiCD58
+ cells
by day 30 (Figure 3C, upper panels). Un-infected
cells showed no outgrowth of LCL (Figure 3C, lower
panels) and were dead after 10 days by Trypan blue
exclusion (data not shown). These findings suggested
that CD23
hiCD58
+ cells were likely to be proliferating.
Figure 3C also shows that neither CD23
loCD58
+ cells nor
CD23
hiCD58
+ cells emerged when B cells from EBV-
seropositive individuals were placed in culture in the
absence of exogenously added EBV.
Proliferation of cells in each sub-population was
examined by exposure of CFSE-labeled B cells to EBV
for five days (Figure 3D). Nearly 80% of CD23
hiCD58
+
cells (R3) had proliferated with 31.7% cells in G1, 38.8%
of cells in G2, and 7.8% of cells in G3. In contrast, the
vast majority of CD23
loCD58
- cells (89.4% in R1) and
CD23
loCD58
+ cells (79.5% in R2) had not proliferated.
The earliest time at which proliferation was observed
was four days after exposure to EBV (data not shown).
Simultaneous examination for expression of IL6 revealed
that 54.4% of CD23
loCD58
+ cells expressed IL6. Mini-
mal to no IL6 expression was observed in CD23
hiCD58
+
cells (7%) and CD23
loCD58
- cells (0%). Thus, expression
of IL6 and proliferation were mutually exclusive
Table 1 Percent CD23
+/CD23
- cells expressing surface molecules or cytokines after exposure of B cells to EBV
Subject 1
0 hr 18 hr 42 hr 66 hr 90 hr 0 hr 18 hr 42 hr 66 hr 90 hr
CD23
+ CD23
-
CD58 1.5 14.5 59.3 50.9 81.2 30.5 45.6 64.9 57.8 59.3
IL6 0.5 2.5 6.8 13.5 44 0.5 0.2 0.2 1.7 1.3
CD57 1 5.4 15.8 27.3 43.2 9.7 8.2 6.5 10.3 8.3
CD86 17.6 23.2 21.2 35.3 38.5 24.5 23.6 36.7 60.4 63.2
MHC CII 99.9 99.6 99.5 99.7 99.9 72.2 75.1 71.8 74.8 69
PD1 14.2 10.8 8.5 9.1 6 5.6 5.6 4.8 6.1 8.6
IL10 0.2 0.1 0.1 0.07 0.09 0.1 0.08 0.09 0.06 0.1
Subject 2
CD58 1 21.5 22.1 38 45.1 39.9 47.6 57.1 54.3 57.6
IL6 0.6 1.6 2.8 14.5 20.7 0.7 1.6 0.9 0.9 0.4
CD57 1.4 3.5 5.3 8.9 17.7 17.6 18.2 14.9 13.7 12.5
CD86 16.8 17.4 15.9 36.2 48.8 34.3 36.5 51.4 54.5 57.5
MHC CII 99.4 99.1 99.2 99.3 99.7 59.2 57.2 61.7 63.4 63.8
PD1 1.8 1.7 1.1 3.9 5.8 2.3 2.1 1 1.7 2.8
IL10 0.1 0.1 0.1 0.04 0.2 0.03 0.04 0.04 0.05 0.08
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hiCD58
+IL6
- was characteristic of cells that underwent
proliferation.
CD23
hiCD58
+ cells do not proliferate in the absence of
EBV-exposed non-proliferating sub-populations of cells
We examined whether CD23
hiCD58
+ cells were able to
proliferate in the absence of EBV-exposed non-prolifer-
ating B cells. Three days after exposure to EBV, FACS-
sorted CD23
hiCD58
+ cells, representing 0.5% of the
culture, were re-introduced into culture after mixing
with un-infected autologous primary B cells as feeder
cells to maintain CD23
hiCD58
+ cells at 0.5% of the cul-
ture. Three day old pre-sort culture and post-sort
CD23
hiCD58
+ c e l l sa r es h o w ni nF i g u r e4 Aa n dB ,
respectively. Un-infected, EBV-exposed, EBV-exposed
but mock-sorted, and mixed culture of sorted-
CD23
hiCD58
+ cells plus un-infected cells were harvested
on day 7. Un-infected B cells gave rise to only 0.04%
CD23
hiCD58
+ cells (C). Un-disturbed EBV-exposed B
cells gave rise to 9.7% (D) and mock-sorted EBV-
exposed B cells gave rise to 7% (E) CD23
hiCD58
+ cells
demonstrating that manipulation of cells during staining
and sorting did not substantially hinder proliferation of
Figure 2 Emergence of distinct sub-populations of B cells expressing CD23 and CD58 following exposure to EBV. B cells from a
representative healthy EBV-seropositive (A) and a representative healthy EBV-seronegative (B) subject were un-infected (left panels) or exposed to
EBV (right panels) and placed in culture. Cells were harvested on day 4 and examined for surface expression of CD23 and CD58. Percent cells in
regions R1 (CD23
loCD58
-), R2 (CD23
loCD58
+), and R3 (CD23
hiCD58
+) are shown.
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hiCD58
+ cells. In contrast, the percentage
of CD23
hiCD58
+ cells four days after mixing sorted-
CD23
hiCD58
+ cells with un-infected cells remained
unchanged (F) as compared to the fraction of
CD23
hiCD58
+ cells in the pre-sorted population (A)
suggesting dependence of CD23
hiCD58
+ cells on the
non-proliferating EBV-exposed sub-populations.
CD23
hi cells and IL6
+ cells can both be derived from
memory B cells
We asked whether susceptibility to proliferation or IL6
expression was pre-determined by the differentiation state
of B cells before infection. Peripheral B cells were FACS-
sorted into CD27
+ memory and CD27
- naïve B cells.
CD27 is considered a general marker for peripheral mem-
ory B cells [17,18]. Sorting strategy and purity of sorted
populations of a representative experiment are shown in
Figure 5A. Simultaneous staining of B cells with CD27 or
matched isotype control antibody allowed detection of
CD27
+ cells prior to sort (data not shown). Sorted cells
were examined on day 5 after exposure to EBV for expres-
sion of CD23 and IL6 (Figure 5B). Since CD23
hiCD58
+
cells underwent proliferation (Figure 3D) and nearly all
CD23
hi cells also expressed CD58 after exposure to EBV
(Figure 2), 5% of memory B cells (CD23
hi) were predicted
to proliferate after exposure to EBV (Figure 5B). In com-
parison, only 0.1% of naïve B cells were CD23
hi.N e a r l y
30% of memory B cells but only 0.2% of naïve B cells
expressed IL6. Among memory B cells, expression of IL6
and expression of high levels of CD23 were mutually
exclusive. Both sub-populations of B cells, whether suscep-
tible to proliferation or expression of IL6, were derived
from memory B cells. Thus, memory or naïve B cells did
not exclusively give rise to either proliferating or IL6-
expressing cells.
Correlations between proliferation, expression of IL6, and
EBV latency gene expression
To determine which sub-populations of CD23
+ cells
expressed viral latency genes, CD23
loCD58
- (R1),
CD23
loCD58
+ (R2), and CD23
hiCD58
+ (R3) cells were
FACS-sorted four days after exposure of B cells to EBV.
A representative experiment showing sorting strategy and
purity of sorted sub-populations is shown in Figure 6A.
Figure 3 CD23
hiCD58
+ cells proliferate and constitute the bulk of the population by day 30. A. Carboxyfluorescein diacetate, succinimidyl
ester (CFSE)-labeled B cells were exposed to EBV and harvested on day 5. CD58
+ cells or CD58
- cells were examined for proliferation and
intracellular expression of IL6 (using APC-anti-IL6 antibody). Percentages represent fraction of gated cells (CD58
+ or CD58
-) producing IL6. G0-3
represents non-proliferated cells (G0) and three generations of progeny (G1-3). Percentages above G0-3 indicate the fraction of CD58
+ or CD58
-
cells in each generation. B. EBV-exposed B cells were harvested on days 5, 6 and 7, and examined for expression of CD23 (PE) and CD58 (PE-
Cy7). Percentages represent fractions of cells in regions R1 (CD23
loCD58
-), R2 (CD23
loCD58
+), and R3 (CD23
hiCD58
+). C. In a separate experiment,
EBV-exposed cells (top panels) were harvested on days 4, 5, 6, 7, 10, and 30 and un-infected cells (bottom five panels) were harvested on days 4,
5, 6, 7, and 10 and examined for expression of CD23 and CD58. Percentages of cells in regions R1, R2, and R3 are shown. EBV-exposed cells
harvested on day 30 and stained with PE and PE-Cy7 isotype control antibodies are also shown. D. CFSE-labeled B cells were exposed to EBV,
harvested on day 5, and examined for expression of CD23 (PE) and CD58 (PE-Cy7). Cells in region R1, R2, and R3 were examined for proliferation
and expression of IL6 (APC) by flow cytometry. Percentages represent fraction of cells in regions R1, R2, or R3 that produced IL6. Percentages
above G0-3 indicate non-proliferating cells (G0) and proliferating cells (G1-3).
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hiCD58
+ and CD23
loCD58
+ sub-populations
expressed EBNA1, LMP1, and EBNA2 transcripts, a pat-
tern consistent with viral type 3 latency which is charac-
teristic of EBV-immortalized B cells (Figure 6B). In
comparison, CD23
loCD58
- cells expressed only EBNA2
mRNA. Since expression of mRNA often does not corre-
late well with expression of protein and because qRT-PCR
is not informative about the fraction of cells expressing a
gene of interest or the level of expression at the single cell
level, we examined EBV-exposed cells for expression of
LMP1 protein at the earliest possible time, on day 3, by
flow cytometry. Figure 6C shows that 87% of CD23
hiCD58
+ cells and 82.3% of CD23
loCD58
+ cells expressed similar
high levels of LMP1 when compared with isotype control
antibody-staining of corresponding sub-populations. In
contrast, only 4.8% of CD23
loCD58
- cells expressed low
levels of LMP1. Sorted cells also demonstrated a similar
pattern of expression of LMP1 in CD23
hiCD58
+ and
CD23
loCD58
+ cells by immunofluorescence (data not
shown). Thus, both distinct sub-populations of cells
namely CD23
hiCD58
+ IL6
- and CD23
loCD58
+ IL6
+
expressed viral latency genes including LMP1, a critical
oncoprotein necessary for growth transformation in LCL
[19]; yet only one of these populations proliferated. This
data also demonstrated that lack of proliferation of
CD23
loCD58
+ cells was not due to lack of transition from
an early EBNA2-expression stage to subsequent LMP1-
expression in this sub-population. Both proliferating
and IL6-expressing sub-populations also expressed high
levels of EBNA2 transcript. Characteristics of the two sub-
populations CD23
hiCD58
+IL6
- and CD23
loCD58
+IL6
+ are
shown in Table 2.
Figure 4 CD23
hiCD58
+ cells do not proliferate in the absence of EBV-exposed non-proliferating sub-populations of cells.T h r e ed a y s
after exposure of CD3-depleted B cells to EBV, CD23
hiCD58
+ cells, representing 0.5% of the culture (A) were FACS-sorted. Post-sort analysis of
CD23
hiCD58
+ cells is shown in B. Sorted CD23
hiCD58
+ cells were mixed with un-infected autologous primary B cells (as feeder cells) and
re-introduced into culture at 0.5% of the total culture. Mock-sorted cells were also re-introduced into culture as control. Cells were harvested four
days later and stained for CD23 (PE) and CD58 (FITC). Un-infected cells (C), EBV-exposed cells (D), mock-sorted but EBV-exposed cells (E), and
sorted-CD23
hiCD58
+ cells mixed with un-infected B cells (F) after a total of 7 days in culture are shown. Percentages represent fraction of
CD23
hiCD58
+ cells out of total.
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hi cells and IL6
+ cells are derived from CD27
+ memory B cells. A. PBMC were FACS-sorted into CD27
+ (memory) and CD27
-
(naïve) B cells. Sorting strategy and purity of cells after sorting are shown. B. Sorted CD27
+ and CD27
- B cells were exposed to EBV. Cells were
harvested on day 5 and examined for expression of CD23 (FITC) and intracellular IL6 (APC) by flow cytometry. Percentages represent IL6
+ or
CD23
hi cells of CD27
+ or CD27
- B cells.
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+ and LMP1
- cells
Figure 6D shows that after exposure of sorted memory
or naïve B cells (as in Figure 5) to EBV, 61.6% of mem-
ory B cells and 19.2% of naïve B cells were LMP1-posi-
tive. Within memory cells, 30.7% (18.9/[18.9 + 42.7]) of
LMP1
+ cells expressed IL6 while 25.8% (9.9/[9.9 + 28.5])
of LMP1
- cells expressed IL6. Although LMP1
+ cells
contributed to two-thirds of the IL6-expressing popula-
tion, LMP1
- cells contributed to the other third. It is
unclear whether this latter population is infected with
EBV. Nearly 20% of naïve B cells expressed LMP1; yet
Figure 6 Proliferating CD23
hiCD58
+ cells and non-proliferating CD23
loCD58
+ cells express EBV latency genes. A. EBV-exposed B cells
were FACS-sorted on day 4 into regions R1 (CD23
loCD58
-), R2 (CD23
loCD58
+), and R3 (CD23
hiCD58
+). Sorting strategy and purity of each
population are shown. Regions were drawn with spaces in between to prevent contamination between regions. B. The relative transcript levels
of latency genes EBNA1, LMP1, and EBNA2 in each of the three sorted sub-populations were determined by real-time reverse transcription-PCR
(qRT-PCR) with gene-specific primers. RNA from already immortalized cells (LCL) from the same subject was used as positive control while RNA
from un-infected PBMC from the same subject was used as negative control. C. EBV-exposed B cells were harvested on day 3 followed by
staining for CD23 (PE), CD58 (PE-Cy7), and intracellular LMP1 (FITC) and flow cytometry. Expression of LMP1 in cells gated on R1, R2, and R3 is
shown. Percentages represent fractions of gated cells expressing LMP1 or detected by the corresponding isotype control antibody. D. Sorted
CD27
+ memory and CD27
- naïve B cells as in the experiment shown in Fig. 5B were exposed to EBV, harvested on day 5, and examined for
expression of intracellular IL6 (APC) and LMP1 (PE). Numbers represent percentages of CD27
+ memory or CD27
- naïve B cells.
Table 2 Characteristics of the two sub-populations of
CD23
+ cells that emerge after exposure to EBV
Proliferating Non-proliferating
CD23 hi lo
CD58 + +
IL6 - +
CD27
+ ++
EBNA1 + +
LMP1 + +
EBNA2 + +
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cells, IL6-producing cells were CD23
lo, non-proliferating
cells (Figure 5B) and LMP1
+ cells largely contributed
towards IL6 expression (Figure 6D), suggesting that the
majority of IL6-producing cells were non-proliferating,
CD23
lo, LMP1
+, memory B cells.
Discussion
This study focuses on early cellular events following
encounter of B cells with EBV. EBV differentially infects
B cells such that sub-populations of cells with distinct
phenotypic and functional characteristics emerge. While
expression of CD23, CD58, and IL6 have been examined
individually either after infection with EBV [6,7,20,21] or
after transfection of EBV latency gene LMP1 [10], to our
knowledge, this is the first report of identification of
sub-populations of B cells based on co-expression of
these molecules, marking EBV-infected cells early for
different outcomes. The expression pattern CD23
hiCD58
+IL6
- predicts the identity of infected cells destined for
proliferation as early as three days after exposure to
EBV. Another sub-population of CD23
+ B cells, also
infected with EBV and expressing EBNA2 and LMP1,
expresses IL6 but fails to proliferate.
Earlier investigations have shown that only cells co-
expressing Epstein-Barr nuclear antigens and CD23
undergo immortalization [11]. These investigations did
not differentiate between the different EB nuclear anti-
gens. Our experiments demonstrate that expression of
EBV latency genes, LMP1 and EBNA2, and CD23, are
not sufficient for proliferation. While low levels of
LMP1 transcripts relative to EBNA2 transcripts in
CD23
loCD58
+ cells suggested lack of transition to high
levels of expression of LMP1 as a potential reason for
their inability to proliferate, LMP1 protein expression
levels in individual cells did not substantiate this possi-
bility. Greater than 80% of CD23
loCD58
+ cells expressed
LMP1 at levels comparable to those observed in
CD23
hiCD58
+ cells. Furthermore, the LMP1 gene pro-
duct appeared to be a latency protein since we did not
observe expression of lytic gene BZLF1 in any of the
sub-populations of cells (data not shown). Thus, B cell
differentiation, abundance of expression of CD23, and
other cellular determinants are among the likely causes
of non-proliferation of CD23
loCD58
+ cells. Whether the
cell surface molecular expression patterns that charac-
terize the two sub-populations are causal to the distinct
outcomes, have other functional significance, or simply
mark the sub-populations is unclear.
We initially infected total peripheral blood B cells with
high titers of EBV to include both naïve and non-naïve
B cells that are thought to be targets of infection during
primary infection with EBV and during the early stages
of development of B cell-EBV lymphomas in
immunocompromised hosts. To better understand
whether the dichotomy in outcome was related to the
differentiation stage of target B cells, we exposed puri-
fied naïve and memory B cells to EBV. Proliferating and
non-proliferating EBV-infected cells did not exclusively
derive from one or the other type of B cells. A related
question, which has been the subject of earlier investiga-
tions, is whether memory B cells serve as direct targets
for EBV-mediated proliferation and immortalization.
Based on experiments that have relied on expression of
viral latency genes for evidence of “immortalization”,i t
has been extrapolated that EBV can immortalize both
memory and naïve B cells [2,3,22]. However, using viral
latency gene expression as evidence for immortalization
may be fallacious as our data demonstrates that expres-
sion of viral latency genes and CD23 during the early
stages of EBV infection does not necessarily correlate
with proliferation and therefore potentially immortaliza-
tion. We have found that while EBV infects both mem-
ory and naïve B cells (Figure 6D) ex vivo,u s i n gt h e
marker pattern that we have identified, it appears that
memory cells can serve as direct targets for EBV-driven
proliferation (Figure 5). The inability of LMP1
+-naïve B
cells to proliferate in our study may be related to the
absence of other types of cells or cytokines such as IL6
in an ex vivo setting.
EBNA2 RNA was the only latency gene product
detected in CD23
loCD58
- cells. Since EBNA2 is not
easily amenable to FACS staining, we were unable to
determine if EBNA2 protein was expressed and if so, in
what fraction of this sub-population, and at what levels.
However, since EBNA2 is a major transactivator of
LMP1 in the early stages of infection [23,24], low levels
of expression of LMP1 protein in a very small fraction
of CD23
loCD58
- cells may serve as an indirect indicator
of deficient EBNA2 protein. Low levels of expression of
CD23 within cells in this sub-population may also con-
tribute to lack of cell proliferation. Certainly lack of
expression of CD23 in EBNA
+ cells is known to prevent
immortalization of B cells [6,7].
IL6 is predominantly expressed by CD23
loCD58
+LMP1
+
cells. Expression of IL6 by non-proliferating cells is consis-
tent with the observation that only rare EBV-immortalized
tonsillar blasts expressed IL6 during primary infection
[25]. IL6 is a growth factor for LCL in culture [20] and in
SCID mice [26]. A strong positive correlation exists
between development of post-transplant EBV-lymphomas
in humans and elevated levels of serum IL6 [27]. It is
tempting to speculate that IL6-producing cells aid the pro-
liferating sub-population, perhaps during the early stages
of EBV-infection via paracrine mechanisms. While the
results of the experiment in Figure 4 argue in favor of this
hypothesis, post-sort mixing experiments will be necessary
to determine the effects of the different sub-populations
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hiCD58
+
cells.
Transfection of LMP1 gene was found to increase
expression of CD58 [9], an adhesion molecule, suggesting
that LMP1 drives expression of CD58 following EBV
infection. We observed a discernible increase in the frac-
tion of CD23
+CD58
+ cells as early as 18 h after exposure
to EBV (Table 1); yet, LMP1 expression has not been
detected earlier than 48 h after exposure to EBV [28]. This
raises the question of an LMP1-independent mode of
expression for CD58. In support of an LMP1-independent
mode of expression of CD58, we found that greater
than 50% of CD23
- cells expressed CD58 around day 3
(Table 1) while fewer than10% of CD23
- cells expressed
LMP1 on day 3 (data not shown).
In the absence of EBV infection, CD58 was expressed
almost exclusively on CD23
- cells (Table 1, time 0),
while after exposure to EBV, expression of CD58 was
up-regulated greatly on CD23
+ cells. Since only a frac-
tion of CD23
+CD58
+ cells proliferated, it is unlikely that
CD58 plays a direct role in proliferation. CD58 may
exert its effects in a broader and more global capacity
to indirectly affect the proliferating population. Indeed
this rapid up-regulation of CD58 may be part of the
immune response alerting the host to infection with
EBV. Interaction of CD58 with its ligand CD2 on T
cells may elicit EBV-directed T cell responses. Interac-
tions between B and T cells were noted following gene
transfer of LMP1 [9].
Although using B cells from healthy EBV-seronegative
individuals may have yielded two potential advantages, we
used cells from healthy EBV-seropositive subjects. First,
depletion of T cells might not have been necessary and
second, “contaminating” naturally infected B cells,
although very few in EBV-seropositive subjects, would
have been absent in cells derived from EBV-seronegative
individuals. However, since most EBV-seronegative indivi-
duals are children and adolescents, it is difficult to obtain
large amounts of blood with each draw. As large volumes
of blood were necessary for our experiments, the majority
of experiments were performed with B cells from healthy
EBV-seropositive individuals. To ensure that naturally
infected B cells did not give rise to proliferating cells, we
tested B cells from all five EBV-seropositive subjects for
outgrowth in culture in the absence of T cells and exogen-
ous EBV. None of the cells showed outgrowth as shown
for one subject in Figure 3C. Thus, although 1-50 out of
10
6 peripheral B cells in EBV-seropositive subjects are
naturally infected with EBV [29], these cells are unable to
grow out in culture even in the absence of T cells. Experi-
ments with cells from two EBV-seronegative subjects
demonstrated emergence of similar sub-populations of B
cells after exposure to EBV (Figure 2B).
Consistent with the work of others [30], between 5%
(Figure 1A) and 15% (data not shown) of peripheral B
cells are CD23
lo while the rest are CD23
- prior to expo-
sure to EBV. Mature B cells express low levels of CD23
[31]. Whether the initial drop in the fraction of CD23
lo
cells following exposure to EBV (Figure 1A) is due to
down-regulation of cell surface expression of CD23 or
death of CD23-expressing cells is unclear. Since CD27
+
memory B cells tend to be CD23
- [ 3 2 ]a n dg i v er i s et o
CD23
hi cells (Figure 5B), it is likely that CD23
hi cells
derive from CD23
- cells. This is consistent with the work
of Azim et al. which suggests that CD23
- cells could
serve as targets for EBV-mediated immortalization [33].
Conclusions
Our findings delineate some of the earliest events after
exposure to EBV and identify a sub-population of
EBV-infected B cells predicted to undergo proliferation
as early as three days aftere x p o s u r et oE B V .A d d i -
tional factors, especially those of cellular origin, are
likely to be important in determining whether an EBV-
infected B cell expressing viral latency genes undergoes
proliferation. The ability to selectively examine cells at
earliest times as they commit to proliferation will be
key to understanding how EBV converts a B cell into a
cell with oncogenic potential. Comparative analyses
between B cells destined for or refractory to EBV-
driven proliferation will yield new avenues of investiga-
tion into EBV pathogenesis and potentially EBV
therapeutics.
Methods
Isolation of B cells
Peripheral Blood Mononuclear Cells (PBMC) were
obtained from healthy adul t s( f i v em a l e sa n dt w o
females) as described [34]. The use of human subjects
was approved by the Human Investigation Committee at
Yale University. Informed written consent was obtained
from volunteers. EBV-seroreactivity was determined by
presence of antibodies to EBNA1 and viral capsid anti-
gen using Western Blot. Experiments were performed
with cells from five EBV-seropositive and two EBV-sero-
negative individuals. Experiments were repeated with
cells from up to six subjects. B cells were isolated using
negative selection by immunomagnetic-depletion of
CD3
+ cells (Invitrogen) with the exception of experi-
ments in Figure 5 and Figure 6D in which B cells were
positively selected and sorted by FACS. Negative selec-
tion of B cells was performed to avoid inadvertent acti-
vation of B cells during isolation. At least 95% of CD19
+
B cells expressed CD21, the receptor for EBV (data not
shown). Monocytes were depleted by adherence to plas-
tic ([35]; data not shown).
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EBV was isolated from the supernatant of B95-8 cells as
described [36]. Infectivity of virus preparations was
assessed by infection in triplicate of EBV-negative BJAB
cells with serial dilutions of virus. After 48 h of culture,
cells were examined for expression of EBNA by indirect
immunofluorescence as described [37] and virus titer
was calculated. Infections were performed using titered
EBV at multiplicity of infection of 50-100 to maximize
the number of infected B cells. After incubation of cells
with virus for two hours at 37°C, cells were washed
twice and placed in culture in the presence of 5% CO2
at 2 × 10
6 ml
-1 in RPMI 1640 containing 10% FBS.
CFSE labeling of cells
Carboxyfluorescein diacetate, succinimidyl ester (CFSE;
Invitrogen) labeling of un-infected B cells was per-
formed as described [38]. We had experimentally deter-
mined that 2 μM CFSE allowed detection of
proliferation for up to four generations with minimal
toxicity to cells (data not shown).
Flow cytometric examination and sorting of cells
Cells were surface-stained with saturating concentra-
tions of antibodies including anti-CD23-PE (BD
Bioscience), anti-CD23-FITC (Dako), anti-CD23-biotin
(BD Bioscience), anti-CD58-FITC (ABD Serotec), anti-
CD58-PE-Cy5 (Biolegend), anti-CD58-biotin (Gene Tex,
Inc.), anti-CD86-APC (BD Bioscience), anti-CD57-FITC
(BD Bioscience), anti-MHC Class II- FITC (BD
Bioscience), anti-PD1-APC (eBioscience), and anti-
CD27-biotin (Biolegend). Murine Ig at 1 mg ml
-1 was
included to inhibit nonspecific binding. Isotype-matched
control antibodies included murine IgG1-PE, IgG1-
FITC, IgM-FITC, IgG2a-FITC, IgG1-APC, IgG1-PE-Cy5,
and IgG1-biotin. Biotinylated antibodies were detected
using Avidin-PE-Cy7 (BD Bioscience) or Avidin-FITC
(Zymed). For intracellular staining, cells were fixed and
permeabilized with Cytofix/Cytoperm (BD Pharmingen)
or 90% cold methanol (for LMP1 staining). Antibodies
included anti-IL6-FITC (eBioscience), anti-IL6-APC
(Biolegend), anti-IL10 Pacific blue (eBioscience), and
anti-LMP1 (CS1-4, Dako) followed by anti-mouse IgG1-
PE or FITC. Isotype control antibodies included murine
IgG2b-FITC, rat IgG1-APC, rat IgG1-Pacific blue, and
murine IgG1. Data was acquired on LSR II (BD
Bioscience) or FACS Calibur and analyzed using
WinMDI. Gates were set on live lymphocytes based on
forward- and side-scatter profiles. Quadrants or gates
were drawn after comparing cells stained with an anti-
body of interest to cells stained with a matched isotype
control antibody. For analysis of cell proliferation, gates
were manually drawn on live cells for each CFSE peak
as described [39,40]. Unlabeled but EBV-exposed cells
and labeled but un-infected cells were used as controls.
Sorting was performed on FACS Vantage or Aria Cell
Sorter.
PCR and qRT-PCR
Primer sequences targeting the BamW fragment of EBV
were: Forward: 5’GACTCCGCCATCCAAGCCTAG3’;
Reverse: 5’TGGACGAGGACCCTTCTACGG3’.
Relative transcript levels of EBV latency genes were
determined by real-time reverse transcription-PCR (qRT-
PCR) of cDNA from sorted cells using gene-specific
primers. Primer sequences were: EBNA1: Forward:
5’AGGGGAAGCCGATTATTTTG3’;
Reverse: 5’CTCCTTGACCACGATGCTTT3’;L M P 1 :
Forward: 5’TGAGTGACTGGACTGGAGGA3’; Reverse:
5’GGCTCCAAGTGGACAGAGAA3’;E B N A 2 :F o r w a r d :
5’CGGTCCCCGACTGTATTTTA3’; Reverse: 5’GGCTC
TGGCCTTGAGTCTTA3’. Relative expression levels
were calculated using standard curves generated from
serial dilutions of EBV
+ Akata Burkitt Lymphoma cell
total RNA and normalized to 18 S rRNA.
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